586 related articles for article (PubMed ID: 25666843)
1. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
2. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
3. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
[TBL] [Abstract][Full Text] [Related]
4. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
5. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
6. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
[TBL] [Abstract][Full Text] [Related]
7. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
9. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
Singh AP; Shah DK
AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
11. Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development.
Khot A; Sharma S; Shah DK
Bioanalysis; 2015; 7(13):1633-48. PubMed ID: 26226312
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
13. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
14. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
Xu S
Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
16. Challenges and advances in the assessment of the disposition of antibody-drug conjugates.
Kamath AV; Iyer S
Biopharm Drug Dispos; 2016 Mar; 37(2):66-74. PubMed ID: 25904406
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
18. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
Zhao L; Shang EY; Sahajwalla CG
J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
[TBL] [Abstract][Full Text] [Related]
19. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.
Zuo P
AAPS J; 2020 Aug; 22(5):105. PubMed ID: 32767003
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]